Editas Medicine Inc. (NASDAQ:EDIT) major shareholder Polaris Venture Management Co. sold 12,819 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $15.77, for a total value of $202,155.63. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Polaris Venture Management Co. also recently made the following trade(s): On Thursday, September 8th, Polaris Venture Management Co. sold 500,000 shares of Editas Medicine stock. The stock was sold at an average price of $16.80, for a total value of $8,400,000.00.
Editas Medicine Inc. (NASDAQ:EDIT) opened at 15.68 on Friday. The company’s 50-day moving average price is $14.53 and its 200-day moving average price is $21.81. Editas Medicine Inc. has a one year low of $12.43 and a one year high of $43.99. The stock’s market capitalization is $558.74 million.
Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.05. Editas Medicine had a negative return on equity of 59.22% and a negative net margin of 1,184.46%. The company earned $1 million during the quarter, compared to analysts’ expectations of $1 million. Editas Medicine’s revenue for the quarter was up 49.3% on a year-over-year basis. Equities research analysts predict that Editas Medicine Inc. will post ($2.49) EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors bought a new position in Editas Medicine during the second quarter worth $115,000. BlackRock Group LTD bought a new position in Editas Medicine during the third quarter worth $117,000. BlackRock Advisors LLC boosted its position in Editas Medicine by 11.2% in the third quarter. BlackRock Advisors LLC now owns 9,817 shares of the company’s stock worth $132,000 after buying an additional 990 shares during the period. PARK CIRCLE Co bought a new position in Editas Medicine during the third quarter worth $135,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in Editas Medicine during the second quarter worth $181,000. 59.88% of the stock is owned by institutional investors.
EDIT has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, September 20th. Jefferies Group reiterated a “buy” rating on shares of Editas Medicine in a report on Monday, August 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $30.75.
About Editas Medicine